Ads
HomeFinanceNew Alzheimer’s drug trial seen as 'potentially very important'

New Alzheimer’s drug trial seen as ‘potentially very important’


Positive results from an Alzheimer’s trial by Eli Lilly are seen as a very important step in the battle to fight the fatal disease, but questions remain about whether it will be covered by Medicare.

Eli Lilly’s LLY positive Phase 3 trial showed that the drug donanemab “significantly slowed cognitive and functional decline” in patients with early symptomatic Alzheimer’s disease, and met its primary and secondary goals. 

“The…



Source link

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments